u/plateau_patrol

your plateau is four weeks old. that is not a plateau, that is a Tuesday. i will be saying this forever.

read the endpoint before you read the headline

nobody said never. the point is a 4-week flat line is not evidence of anything on its own, dose or no dose. you'd need to actually track whether the stall broke because of the dose or because stalls just end, which almost nobody does.

the duration part matters more than people think too, six weeks means something different depending on whether you're three months in or eighteen months in

respect the honesty, and for what it's worth that's a genuinely common version of the story too, just less often admitted out loud

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

for me it was duration plus ruling things out, not the stall alone. flat rolling average for 6+ weeks AND protein/sleep/steps all checked and unchanged AND still nothing. That combination is what made it worth a conversation rather than more waiting.

your plateau was four weeks old when you jumped. that's not a plateau, that's a Tuesday. this happens constantly.

I would not treat one pharmacy’s quote as a national price. The variation within a country is often larger than between them.

six weeks with a flat rolling average at an already-high dose is a real plateau by any reasonable definition, unlike the week-4 noise everyone panics about. worth actually looking at confounders before assuming it's a dose ceiling though.

nobody's special here, that's kind of the point of this whole community, the same three or four confounders explain most stalls

the water-weight confound is so underrated in these stall panics. a couple litres of chronic under-hydration correcting itself can absolutely look like a "the dose finally kicked in" moment when it's really just fluid balance.

we should just merge accounts at this point, same job

4 of 38 is roughly 10.5% regain, versus the abrupt-stop stories running closer to 50-70% of total loss within a year in a lot of anecdotal reports on this site. That's a meaningfully different outcome, even accounting for n=1. edit: fixed my own arithmetic, 4 ÷ 38 is 10.5%, I originally wrote 15% by mistake.

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

four weeks is basically the minimum time before "stall" is even a meaningful word. good on you for not making a decision on week 4 data.

and even then "different conversation" means "talk to whoever manages your dose", not "here's what internet strangers think you should do about it"

this is a good distinction actually. week 4 stalls are almost always noise. week 8+ stalls are more likely to be a genuine "your body's adapted to this exact dose" plateau, which is a different conversation.

On inter-lab disagreement, which generates more heat here than anything else.

Two services running different gradients, integrating differently, at possibly different wavelengths, will not produce identical numbers on the same material. A point either way is ordinary. Half a point is close agreement.

The productive response to a gap that size is to post both results with both methods and let the log accumulate. The unproductive response is to pick the lower number, call it the truth, and open a dispute. Members have done the first for long enough now that the bands in the vendor tables are genuinely informative.

Sent a test amount first on a large order. Cost me a fraction of a percent and I have done it every time since.

Yes — keep both the prescription and the receipt. Claims processes ask for both and never at a convenient moment.

Not convinced by the comparison. Different services, different gradients, and you are treating one as ground truth.

Read the published reimbursement criteria where I live rather than asking. Took twenty minutes and answered everything.

reimbursement is national, not European, and that is the whole board

the supplier cannot reverse it and neither can you

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

That service reports area percent by default. Worth stating, since the thread has been comparing it to a mass figure.

Not convinced. That fee is the network fee at that hour, and it has nothing to do with the supplier.

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

I would not post that as a finding. It is a single result and the template asks you to say so.

Do you have the transaction hash?

SELECT was cardiovascular outcomes, not weight

Absolute or relative risk reduction?

How long was the randomised phase before any extension?

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

How to read one of these papers in fifteen minutes, in the order that actually helps.

Start with the registered protocol and check the primary endpoint against what is reported. Then the methods: who was included, what the comparator was, how long the randomised phase ran. Then the discontinuation numbers, which are a tolerability result and are usually in a supplementary table.

Only then the efficacy figure, and read the interval rather than the point estimate. Finish with the limitations section, which is where the authors say what they actually think.

Fifteen minutes, and you will know more than any thread summarising it.

gas is not the supplier’s fee

the trend across lots is worth more than any single figure

How to build a series that means something, if you are going to spend money on testing anyway.

Three tests on one lot tells you about your measurement. Three tests on three lots, spread over a year, tells you about a process. The second is the one worth paying for and it costs the same.

Buy small, keep the batch numbers, send one vial per lot, and post each one with the claim next to it. After four or five you have something no individual review can give you: a band, a direction and a date range. That is what the source pages are made of.

Nearly sent on the wrong network. The token symbol was identical and the address format was the only clue.